Core Viewpoint - Biotalys NV has received a transparency notification from Sofinnova Partners SAS regarding its shareholding, indicating that Sofinnova now holds 9.93% of Biotalys' voting rights as of June 11, 2025 [1][2]. Company Information - Biotalys is an Agricultural Technology (AgTech) company focused on developing protein-based biocontrol solutions aimed at sustainable crop protection, providing alternatives to conventional chemical pesticides [5]. - The company utilizes its AGROBODY™ technology platform to create a diverse pipeline of product candidates targeting key crop pests and diseases throughout the agricultural value chain [5]. - Founded in 2013 as a spin-off from the VIB (Flanders Institute for Biotechnology), Biotalys has been listed on Euronext Brussels since July 2021 and is based in Ghent, Belgium [5]. Shareholding Details - As of June 11, 2025, Sofinnova Partners SAS holds 3,719,820 shares of Biotalys, which corresponds to 9.93% of the total voting rights [2][6]. - The previous notification indicated that Sofinnova held 4,226,962 voting rights, showing a decrease in their holdings [3]. - The threshold crossed by Sofinnova was 10%, with a total denominator of 37,470,062 shares [6].

Core Viewpoint - Biotalys has appointed Luc Van fraeyenhoven as the new Chief Financial Officer (CFO) to lead finance operations as the company advances its product pipeline towards commercialization [2][4]. Company Overview - Biotalys is an Agricultural Technology (AgTech) company focused on developing protein-based biocontrol solutions aimed at providing alternatives to conventional chemical pesticides for sustainable crop protection [5]. - The company utilizes its AGROBODY™ technology platform to create a diverse pipeline of product candidates targeting key crop pests and diseases [5]. - Founded in 2013 as a spin-off from the VIB (Flanders Institute for Biotechnology), Biotalys has been listed on Euronext Brussels since July 2021 and is based in Ghent, Belgium [5]. Leadership Transition - Luc Van fraeyenhoven, with over three decades of financial experience, will succeed Douglas Minder as CFO [2][3]. - Van fraeyenhoven has held CFO positions in various biotechnology and medtech companies, including Arseus Medical and ActoBio Therapeutics, and has significant experience in finance operations and strategy [3]. - The transition is expected to occur over the next few months, with Van fraeyenhoven expressing eagerness to contribute to Biotalys' innovative technology [2][4]. Strategic Importance - The appointment of Van fraeyenhoven is seen as crucial for Biotalys as it seeks to commercialize its first products while managing resources effectively [4]. - The leadership change is anticipated to enhance financial guidance on both long-term strategies and daily operations [4].